Intravenous iron in chemotherapy-induced anemia

American Journal of Hematology

Volumn 89, Issue 12, 2014, Pages 1153-1153

  Auerbach, Michael ^a  

^a Auerbach Hematology and Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN; IRON;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CHEMOTHERAPY INDUCED ANEMIA; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENTION TO TREAT ANALYSIS; IRON THERAPY; LETTER; LYMPHOPROLIFERATIVE DISEASE; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RISK REDUCTION; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; ANEMIA; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DRUG POTENTIATION; INTRAVENOUS DRUG ADMINISTRATION;

ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG SYNERGISM; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; PRACTICE GUIDELINES AS TOPIC;

EID: 84922392484     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23883     Document Type: Letter

References (11)

1. Centers for Medicare and Medicaid Services. Decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). Available at: http://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id203d.pdf. Published 2008. Accessed on July 1, 2012.
2. Ludwig H, Aapro M, Bokemeyer C, et al. A European patient record study on diagnosis and treatment of chemotherapy-induced anemia. Support Care Center 2014;22:2197-2206.
3. Steensma D, Sloan J, Dakhil S, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011:29:97-105.
4. Steensma D, Sasu B, Tomita D, et al. The relationship between serum hepcidin levels and clinical outcome in patients with chemotherapy-associated anemia treated in a controlled trial [ASCO abstract 9031]. J Clin Oncol 2011;29(15 suppl l).
5. Auerbach M, Liang A, Glaspy G. Intravenous iron in chemotherapy and cancer-related anemia. Commun Oncol 2012;9:289-295.
6. Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anemia-Systematic review and meta-analysis of randomised trials. Acta Oncol 2013;52:18-29.
7. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukaemia 2008;22:462-477.
8. Beguin Y, Maertens J, De Prijck B, et al. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: A prospective multicenter randomized trial. Am J Hematol 2013;88:990-996.
9. Steinmetz H, Tschechne B, Virgin G, et al. Clinical exeperience with ferric carboxymaltose in the treatment of cancer-and chemotherapy-associated anaemia. Ann Oncol 2013;24:475-482.
10. Loo M, Beguin Y. The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. Blood 1999;93:3286-3293.
11. Henry D, Dahl N, Auerbach M. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol 2012;87:308-310.